Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Plos One
|
September 7, 2017
Characterization of the microDNA through the response to chemotherapeutics in lymphoblastoid cell lines
Pamela Mehanna, Vincent Gagné, Mathieu Lajoie, et al.
Annals of Surgical Oncology
|
April 22, 2020
Dynamic Neutrophil-to-Lymphocyte Ratio: A Novel Prognosis Measure for Triple-Negative Breast Cancer
Dan Moldoveanu, Vera Pravongviengkham, Gordie Best, et al.
Haematologica
|
August 20, 2016
CLIC5: a novel ETV6 target gene in childhood acute lymphoblastic leukemia
Benjamin Neveu, Jean-François Spinella, Chantal Richer, et al.
Plos One
|
March 28, 2017
Specific expression of novel long non-coding RNAs in high-hyperdiploid childhood acute lymphoblastic leukemia
Mathieu Lajoie, Simon Drouin, Maxime Caron, et al.
BMC Molecular Biology
|
November 20, 2008
The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals
Rebecca S LaRue, Stefán R Jónsson, Kevin A T Silverstein, et al.
Nature Cancer
|
February 5, 2022
Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma
Rached Alkallas, Mathieu Lajoie, Dan Moldoveanu, et al.
Oncogene
|
December 22, 2018
Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma
Fida Khater, Sylvie Langlois, Pauline Cassart, et al.
Molecular Biosystems
|
May 18, 2012
Galvestine-1, a novel chemical probe for the study of the glycerolipid homeostasis system in plant cells
Laurence Boudière, Cyrille Y Botté, Nadia Saidani, et al.
Cell Reports
|
April 6, 2022
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
Shivshankari Rajkumar, Diana Berry, Kayla A Heney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2018
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
Matthew Dankner, Mathieu Lajoie, Dan Moldoveanu, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Plos One
|
September 7, 2017
Characterization of the microDNA through the response to chemotherapeutics in lymphoblastoid cell lines
Pamela Mehanna, Vincent Gagné, Mathieu Lajoie, et al.
Annals of Surgical Oncology
|
April 22, 2020
Dynamic Neutrophil-to-Lymphocyte Ratio: A Novel Prognosis Measure for Triple-Negative Breast Cancer
Dan Moldoveanu, Vera Pravongviengkham, Gordie Best, et al.
Haematologica
|
August 20, 2016
CLIC5: a novel ETV6 target gene in childhood acute lymphoblastic leukemia
Benjamin Neveu, Jean-François Spinella, Chantal Richer, et al.
Plos One
|
March 28, 2017
Specific expression of novel long non-coding RNAs in high-hyperdiploid childhood acute lymphoblastic leukemia
Mathieu Lajoie, Simon Drouin, Maxime Caron, et al.
BMC Molecular Biology
|
November 20, 2008
The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals
Rebecca S LaRue, Stefán R Jónsson, Kevin A T Silverstein, et al.
Nature Cancer
|
February 5, 2022
Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma
Rached Alkallas, Mathieu Lajoie, Dan Moldoveanu, et al.
Oncogene
|
December 22, 2018
Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma
Fida Khater, Sylvie Langlois, Pauline Cassart, et al.
Molecular Biosystems
|
May 18, 2012
Galvestine-1, a novel chemical probe for the study of the glycerolipid homeostasis system in plant cells
Laurence Boudière, Cyrille Y Botté, Nadia Saidani, et al.
Cell Reports
|
April 6, 2022
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
Shivshankari Rajkumar, Diana Berry, Kayla A Heney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2018
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
Matthew Dankner, Mathieu Lajoie, Dan Moldoveanu, et al.
Page
of 3